Volume 25, Number 1—January 2019
CME ACTIVITY - Research
Prescription of Antibacterial Drugs for HIV-Exposed, Uninfected Infants, Malawi, 2004–2010
Table 4
Variable |
Overall | Before CPT | After CPT | p values† | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total no. |
Per person |
Per infant-month |
Total no. |
Per person |
Per infant-month |
Total no. |
Per person |
Per infant-month |
Per person |
Per person-month |
||||
No. |
2,152 |
692 |
1,460 |
|||||||||||
Median follow-up time, d |
600,562 |
336 (255–340) |
187,865 |
337 (226–343) |
412,697 |
336 (294–339) |
0.09 |
|||||||
Prescriptions, total | 5,107 | 2 (1–3) | 0.2 (0.1–0.3) | 2,269 | 3 (1–5) | 0.3 (0.2–0.5) | 28,38 | 2 (1–3) | 0.2 (0.1–0.3) | <0.0001 | <0.0001 | |||
For respiratory infections | 3,437 | 1 (0–2) | 0.1 (0–0.2) | 1481 | 2 (1–3) | 0.2 (0.1–0.3) | 1956 | 1 (0–2) | 0.1 (0.0–0.2) | <0.0001 | <0.0001 | |||
For other infections | 1,670 | 0 (0–1) | 0 (0–0.1) | 788 | 1 (0–2) | 0.1 (0–0.2) | 882 | 0 (0–1) | 0.0 (0.0–0.1) | <0.0001 | <0.0001 |
*Overall and according to baseline visit timing relative to CPT guideline implementation (June, 2006). Values are range (IQR) except as indicated. CPT, cotrimoxazole prophylaxis; IQR, interquartile range.
†p values based on Kruskal-Wallis test for continuous variables.
1Team members are listed at the end of this article.
Page created: December 12, 2018
Page updated: December 12, 2018
Page reviewed: December 12, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.